Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Summary
Myosin Therapeutics received a $4.5 million NCI SBIR Phase IIB Bridge Award to support its STAR-GBM Phase I trial of MT-125 in glioblastoma. The company will use the funding to advance dose escalation and expansion work in newly diagnosed MGMT unmethylated glioblastoma. MT-125 targets non-muscle myosin II and aims to address tumor invasion, proliferation, and treatment resistance. Patient enrollment is set to begin in November, and the company expects the data to support later-stage development and potential partnerships.
Funding
Amount
$4.5M
Total raised
Date
August 19, 2025
Announcement date
Investors
National Cancer Institute
Lead investors
Company
myosintherapeutics.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected